Medtronic plc (BIT:1MDT)
Italy · Delayed Price · Currency is EUR | Market Cap | 100.91B -0.7% |
| Revenue (ttm) | 31.06B +8.4% |
| Net Income | 4.10B +3.0% |
| EPS | 3.19 +3.3% |
| Shares Out | n/a |
| PE Ratio | 24.61 |
| Forward PE | 15.29 |
| Dividend | 2.46 (3.11%) |
| Ex-Dividend Date | Jun 25, 2026 |
| Volume | 116 |
| Open | 77.92 |
| Previous Close | 78.86 |
| Day's Range | 77.92 - 79.14 |
| 52-Week Range | 63.14 - 93.74 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 1, 2026 |
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and rem... [Read more]
Financial Performance
In fiscal year 2026, Medtronic's revenue was $36.36 billion, an increase of 8.43% compared to the previous year's $33.54 billion. Earnings were $4.80 billion, an increase of 2.98%.
Financial numbers in USD Financial StatementsNews
I've Got Royalty on the Brain
And how could I not? After exploring Brighton Beach and Bristol, and then Cornwall all the way to St. Ives and Penzance, I wrapped up my Great Britain trip with a couple days in London.
Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias
Sphere-9 all-in-one mapping and ablation, large-tip focal, dual energy catheter first to be CE Marked for ventricular ablation New indication marks important milestone for ventricular arrhythmia patie...
A new era for surgery with real-time AI: Medtronic to unveil Touch Surgery™ Aide, the next-generation compute platform for the operating room at Society of Robotic Surgery 2026
Advanced compute power, built on NVIDIA infrastructure, enables real-time decision support during the procedure FDA-cleared Instrument Exit Point (IEP), the first real-time AI application for robotic ...
Medtronic to announce financial results for its first quarter of fiscal year 2027
GALWAY, Ireland, July 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, September 1, 2026,...
Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain
Acquisition adds category-defining SPRINT® PNS technology to Medtronic's pain therapy portfolio—the broadest in the industry.¹ GALWAY, Ireland, July 16, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT),...
This Undervalued Medical-Devices Stock Is Poised for a Rebound
Medtronic offers high growth potential in addition to discounted valuation.
Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
Acquisition delivers simplicity and access, supporting physicians across the full procedural workflow GALWAY, Ireland, June 12, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healt...
As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play
Tech stocks are pulling back, and healthcare is surging.
Medtronic Earnings Call Transcript: Q4 2026
Q4 and FY26 delivered strong revenue and EPS growth, with robust performance across key segments and significant progress in innovation and portfolio focus. FY27 guidance anticipates continued top-line acceleration, margin leverage, and ongoing investment despite tariff and macro headwinds.
Medtronic Earnings release: Q4 2026
Medtronic released its Q4 2026 earnings on June 3, 2026, summarizing the period's financial results.
Medtronic Slides: Q4 2026
Medtronic has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on June 3, 2026.
Medtronic Annual report: Q4 2026
Medtronic has published its Q4 2026 annual report on June 3, 2026.
Medtronic Stock Rises on Earnings. Wall Street Looks Past a Soft Outlook.
The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts' estimates.
Medtronic Posts Higher Profit, Sales
Medtronic said its profit and sales rose during its fiscal fourth quarter, reflecting steps the company has taken to improve business performance and drive growth.
Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
Company also announces 510(k) pending for LigaSure™ RAS Maryland instrument on the Hugo RAS system, and 510(k) clearance for ProGrip™ Advanced self-gripping polypropylene mesh for use in robotic-assis...
Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens
Investments in intracardiac echocardiography (ICE) technologies highlight Medtronic's commitment to driving durable growth in the cardiac ablation business through a differentiated portfolio of techno...
Medtronic beats quarterly estimates on robust demand for heart devices
Medtronic beat Wall Street estimates for fourth-quarter revenue and adjusted profit on Wednesday, riding the wave of steady demand for its heart devices used in complex cardiac procedures.
Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
GALWAY, Ireland, June 3, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2026 (F...
7 Dividend Stocks to Beat Inflation
Historically, energy stocks have performed the best when inflation spikes.
Medtronic plans to buy SPR Therapeutics for $650 million to expand pain treatment options
Medical device maker Medtronic said on Wednesday it plans to acquire privately held SPR Therapeutics for about $650 million in cash, expanding its portfolio of treatments for chronic pain.
Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain
Acquisition will enhance Medtronic's Neuromodulation portfolio with temporary peripheral nerve stimulation (PNS) technology, enabling earlier intervention for chronic pain sufferers GALWAY, Ireland, M...
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) evaluating Atrioventricular Interval Mod...